Drugs that Affect Platelet Function^[*]

Abstract

Drugs represent the most common cause of platelet dysfunction in our overmedicated society. While acetylsalicylic acid (aspirin), adenosine diphosphate receptor antagonists (clopidogrel and prasugrel), and integrin αIIbβ3 (GPIIb-IIIa) receptor blockers (abciximab, eptifibatide, and tirofiban) are well-known prototypes of antiplatelet drugs, other widely used agents such as nonsteroidal anti-inflammatory drugs, antibiotics, cardiovascular and lipid-lowering drugs, selective serotonin reuptake inhibitors, and volume expanders can also impair platelet function and thus cause or aggravate hemorrhages in certain clinical settings. Therefore, induction of a bleeding diathesis remains a significant concern. This is especially relevant in patients with preexisting hemostatic defects of any kind, which may remain compensated as long as platelet function (and/or coagulation) is not inhibited pharmacologically. Identification of individual patients with preexisting hemostatic defects remains crucial (1) to prevent otherwise unexpected bleeding complications, (2) to manage hemorrhagic symptoms adequately, (3) to minimize the risk from invasive procedures, and (4) to avoid unnecessary patient exposure to blood products. This article provides a review of the large variety of agents that have not been designed for antiplatelet therapy but nevertheless interfere with platelet reactivity or induce platelet inhibition. In particular, drug interactions and mechanisms by which these agents can trigger or cause platelet dysfunction are detailed.

Keywords

nonsteroidal anti-inflammatory drugs (NSAIDs) - antibiotics - cardiovascular and lipid-lowering drugs - psychotropic agents - drug interactions

^* Dedicated to the memory of Professor E.F. Lüscher and Professor W. Schneider

• References

• 1 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes [first of two parts]. N Engl J Med 1992; 326 (4) 242-250
• 2 Ruggeri ZM. Platelet interactions with vessel wall components during thrombogenesis. Blood Cells Mol Dis 2006; 36 (2) 145-147
• 3 Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007; 100 (12) 1673-1685
• 4 Iannacone M, Sitia G, Isogawa M , et al. Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A 2008; 105 (2) 629-634
• 5 Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23 (12) 2131-2137
• 6 Boucharaba A, Serre CM, Grès S , et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004; 114 (12) 1714-1725
• 7 Gupta GP, Massagué J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest 2004; 114 (12) 1691-1693
• 8 Semple JW, Italiano Jr JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11 (4) 264-274
• 9 Ruggeri ZM. Platelet adhesion under flow. Microcirculation 2009; 16 (1) 58-83
• 10 Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005; (4) CD001925
• 11 Antithrombotic Trialists'(ATT) Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329) 71-86
• 12 Antithrombotic Trialists' (ATT) Collaboration. Baigent C, Blackwell L , et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678) 1849-1860
• 13 Scharf RE. Management of bleeding in patients using antithrombotic agents: prediction, prevention, protection and problem-oriented intervention. Hamostaseologie 2009; 29 (4) 388-398
• 14 Eikelboom JW, Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J Thromb Haemost 2007; 5 (Suppl. 01) 255-263
• 15 May AE, Geisler T, Gawaz M. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. Thromb Haemost 2008; 99 (3) 487-493
• 16 Scharf RE. Acquired platelet function defects: an underestimated but frequent cause of bleeding complications in clinical practice. In: Scharf RE, , ed. Progress and Challenges in Transfusion Medicine, Hemostasis, and Hemotherapy. Freiburg, Germany: Karger; 2008: 296-316
• 17 Shattil S, Bennett J. Acquired qualitative platelet disorders due to diseases, drugs, and foods. In: Beutler E, Lichtman MA, Coller BS, Kipps TH, , eds. Williams Hematology. 5th ed. New York, NY: McGraw-Hill; 1995: 1386-1400
• 18 Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010; 9 (2) 154-169
• 19 Catella-Lawson F, Reilly MP, Kapoor SC , et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345 (25) 1809-1817
• 20 Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 199S-233S
• 21 Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330 (18) 1287-1294
• 22 Seidel H, Rahman MM, Scharf RE. Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives. Hamostaseologie 2011; 31 (1) 41-51
• 23 Santilli F, Rocca B, De Cristofaro R , et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol 2009; 53 (8) 667-677
• 24 Patrono C, Andreotti F, Arnesen H , et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32 (23) 2922-2932
• 25 Scharf RE, Rahman MM, Seidel H. The impact and management of acquired platelet dysfunction. Hamostaseologie 2011; 31 (1) 28-40
• 26 Ferri A, Calza R, Pellegrini A, Cattani L. Two distinct mechanisms of inhibition of platelets aggregation by acetylsalicylic acid. Biochem Mol Biol Int 1994; 32 (6) 1101-1107
• 27 Turner NA, Moake JL, Kamat SG , et al. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation 1995; 91 (5) 1354-1362
• 28 Schrör K. Acetylsalicylsäure. 2nd ed. Frechen, Germany: Dr. Schrör Verlag; 2011: 324-329
• 29 Weksler BB. Regulation of prostaglandin synthesis in human vascular cells. Ann N Y Acad Sci 1987; 509: 142-148
• 30 Kaneshiro MM, Mielke Jr CH, Kasper CK, Rapaport SI. Bleeding time after aspirin in disorders of intrinsic clotting. N Engl J Med 1969; 281 (19) 1039-1042
• 31 Thomas P, Hepburn B, Kim HC, Saidi P. Nonsteroidal anti-inflammatory drugs in the treatment of hemophilic arthropathy. Am J Hematol 1982; 12 (2) 131-137
• 32 Ragni MV, Miller BJ, Whalen R, Ptachcinski R. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. Am J Hematol 1992; 40 (3) 176-182
• 33 Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002; 9 (5) 407-415
• 34 Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34 (8) 709-733
• 35 Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost 2009; 7 (Suppl. 01) 258-261
• 36 George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991; 324 (1) 27-39
• 37 The Steering Committee of the Physicians' Health Study Research Group. Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988; 318 (4) 262-264
• 38 The Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321 (3) 129-135
• 39 Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35 (3) 219-226
• 40 Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340 (24) 1888-1899
• 41 Lee M, Cryer B, Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med 1994; 120 (3) 184-189
• 42 Wallace JL, Ma L. Inflammatory mediators in gastrointestinal defense and injury. Exp Biol Med (Maywood) 2001; 226 (11) 1003-1015
• 43 Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A 2001; 98 (11) 6470-6475
• 44 Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90 (7) 2515-2521
• 45 Mielke Jr CH. Comparative effects of aspirin and acetaminophen on hemostasis. Arch Intern Med 1981; 141 (3 spec no) 305-310
• 46 Kasper CK, Rapaport SI. Bleeding times and platelet aggregation after analgesics in hemophilia. Ann Intern Med 1972; 77 (2) 189-193
• 47 Sattler FR, Weitekamp MR, Ballard JO. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med 1986; 105 (6) 924-931
• 48 Burroughs SF, Johnson GJ. Beta-lactam antibiotic-induced platelet dysfunction: evidence for irreversible inhibition of platelet activation in vitro and in vivo after prolonged exposure to penicillin. Blood 1990; 75 (7) 1473-1480
• 49 Wisløff F, Godal HC. Prolonged bleeding time with adequate platelet count in hospital patients. Scand J Haematol 1981; 27 (1) 45-50
• 50 Shattil SJ, Bennett JS, McDonough M, Turnbull J. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest 1980; 65 (2) 329-337
• 51 Koscielny J, Ziemer S, Radtke H , et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004; 10 (3) 195-204
• 52 Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M. Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med 1986; 146 (11) 2159-2164
• 53 Uchida K, Kakushi H, Shike T. Effect of latamoxef (moxalactam) and its related compounds on platelet aggregation in vitro—structure activity relationships. Thromb Res 1987; 47 (2) 215-222
• 54 Mihara S, Kakushi H, Shike T , et al. Effects of latamoxef on in vitro and ex vivo thromboxane A2 generation in human platelets. Thromb Res 1988; 49 (2) 215-224
• 55 Lipsky JJ. Antibiotic-associated hypoprothrombinaemia. J Antimicrob Chemother 1988; 21 (3) 281-300
• 56 Ishikawa S, Manabe S, Wada O. Miconazole inhibition of platelet aggregation by inhibiting cyclooxygenase. Biochem Pharmacol 1986; 35 (11) 1787-1792
• 57 Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72 (4) 634-646
• 58 Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003; 92 (9A) 9M-18M
• 59 Halcox JP, Nour KR, Zalos G , et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40 (7) 1232-1240
• 60 Scharf RE, Zotz RB. Blood platelets and myocardial infarction: do hyperactive platelets really exist?. Transfus Med Hemother 2006; 33 (2) 189-199
• 61 Torfgård KE, Ahlner J. Mechanisms of action of nitrates. Cardiovasc Drugs Ther 1994; 8 (5) 701-717
• 62 Dash D, Rao K. Effect of propranolol on platelet signal transduction. Biochem J 1995; 309 (pt 1) 99-104
• 63 Larsson P, Olsson G, Hjemdahl P. Influence of beta-1-blockade on alterations in human platelet aggregability by mental stresss and adrenaline infusion (Abstract). Eur J Pharmacol 1990; 183: 332
• 64 Knight CJ, Panesar M, Wilson DJ , et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997; 95 (1) 125-132
• 65 Johnson GJ, Leis LA, Francis GS. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets. Circulation 1986; 73 (4) 847-854
• 66 Scharf RE. Thrombozyten und Mikrozirkulationsstörungen. Stuttgart, Germany: Schattauer; 1986
• 67 Hjemdahl P, Wallén NH. Calcium antagonist treatment, sympathetic activity and platelet function. Eur Heart J 1997; 18 (suppl A) A36-A50
• 68 Lawson D, Mehta J, Mehta P, Lipman BC, Imperi GA. Cumulative effects of quinidine and aspirin on bleeding time and platelet alpha 2-adrenoceptors: potential mechanism of bleeding diathesis in patients receiving this combination. J Lab Clin Med 1986; 108 (6) 581-586
• 69 Zahno A. Drug interactions and hepatotoxicity of clopidogrel. [PhD dissertation]. Faculty of Science, University of Basel, Switzerland; 2010
• 70 Zurbano MJ, Anguera I, Heras M , et al. Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIa in early postmyocardial infarction stage. Arterioscler Thromb Vasc Biol 1999; 19 (7) 1791-1795
• 71 Bauriedel G, Skowasch D, Schneider M, Andrié R, Jabs A, Lüderitz B. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. Am Heart J 2003; 145 (2) 343-348
• 72 Serebruany VL, Pokov AN, Malinin AI , et al. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am Heart J 2006; 151 (1) 92-99
• 73 Shankar RP, Bhargava VK, Grover A, Majumdar S, Garg SK. Involvement of nitric oxide in the antiaggregatory effect of enalapril. Methods Find Exp Clin Pharmacol 2001; 23 (5) 255-257
• 74 Chłopicki S, Koda M, Chabielska E, Buczko W, Gryglewski RJ. Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition. J Physiol Pharmacol 2000; 51 (4 pt 1) 715-722
• 75 Sadowitz B, Seymour K, Costanza MJ, Gahtan V. Statin therapy—Part II: Clinical considerations for cardiovascular disease. Vasc Endovascular Surg 2010; 44 (6) 421-433
• 76 Sadowitz B, Maier KG, Gahtan V. Basic science review: Statin therapy—Part I: The pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg 2010; 44 (4) 241-251
• 77 Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002; 22 (10) 1524-1534
• 78 Nissen SE, Tuzcu EM, Schoenhagen P , et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352 (1) 29-38
• 79 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352 (16) 1685-1695
• 80 Labiós M, Martínez M, Gabriel F, Guiral V, Martínez E, Aznar J. Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry. Thromb Res 2005; 115 (4) 263-270
• 81 Haramaki N, Ikeda H, Takenaka K , et al. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol 2007; 27 (6) 1471-1477
• 82 Osamah H, Mira R, Sorina S, Shlomo K, Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997; 44 (1) 77-83
• 83 Shattil SJ, Anaya-Galindo R, Bennett J, Colman RW, Cooper RA. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975; 55 (3) 636-643
• 84 Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110 (3) 285-288
• 85 Ghittoni R, Patrussi L, Pirozzi K , et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 2005; 19 (6) 605-607
• 86 Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97 (12) 1232-1235
• 87 Carvalho AC, Colman RW, Lees RS. Clofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia. Circulation 1974; 50 (3) 570-574
• 88 Ortega MP, Sunkel C, Armijo M, Priego JG. Effects of etofibrate on platelet function: in vitro studies in human plasma. Thromb Res 1980; 19 (3) 409-416
• 89 Heiden D, Mielke Jr CH, Rodvien R. Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release. Br J Haematol 1977; 36 (3) 427-436
• 90 Warkentin TE, Greinacher A , eds. Heparin-Induced Thrombocytopenia. 3rd ed. New York: Marcel Dekker; 2004: 53-106 , 335–370
• 91 Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113 (20) 4970-4976
• 92 Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97 (3) 251-256
• 93 Horne III MK, Hutchison KJ. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 1998; 58 (1) 24-30
• 94 Sobel M, Fish WR, Toma N , et al. Heparin modulates integrin function in human platelets. J Vasc Surg 2001; 33 (3) 587-594
• 95 Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ. Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling. Blood 2011; 117 (18) 4946-4952
• 96 Schafer AI, Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 1985; 75 (2) 456-461
• 97 Winters KJ, Santoro SA, Miletich JP, Eisenberg PR. Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation 1991; 84 (4) 1552-1560
• 98 Penny WF, Ware JA. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator. Blood 1992; 79 (1) 91-98
• 99 Green D, Ts'ao CH, Cerullo L, Cohen I, Ruo TI, Atkinson Jr AJ. Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis. J Lab Clin Med 1985; 105 (3) 321-327
• 100 Langdell RD, Adelson E, Furth FW, Crosby WH. Dextran and prolonged bleeding time; results of a sixty-gram, one-liter infusion given to one hundred sixty-three normal human subjects. J Am Med Assoc 1958; 166 (4) 346-351
• 101 Weiss HJ. The effect of clinical dextran on platelet aggregation, adhesion, and ADP release in man: in vivo and in vitro studies. J Lab Clin Med 1967; 69 (1) 37-46
• 102 Aberg M, Hedner U, Bergentz SE. Effect of dextran on factor VIII (antihemophilic factor) and platelet function. Ann Surg 1979; 189 (2) 243-247
• 103 Kline A, Hughes LE, Campbell H, Williams A, Zlosnick J, Leach KG. Dextran 70 in prophylaxis of thromboembolic disease after surgery: a clinically oriented randomized double-blind trial. BMJ 1975; 2 (5963) 109-112
• 104 Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 1980; 17 (4) 259-291
• 105 Mishler IV JM. Synthetic plasma volume expanders—their pharmacology, safety and clinical efficacy. Clin Haematol 1984; 13 (1) 75-92
• 106 Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007; 9 (1) 47-59
• 107 Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?. Am J Med 2006; 119 (2) 113-116
• 108 Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, Egberts AC. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med 2003; 163 (19) 2354-2358
• 109 Sewnath ME, van Hillegersberg R, Koopman MM, Levi MM, Gouma DJ. [Increased perioperative blood loss during treatment with paroxetine]. Ned Tijdschr Geneeskd 2002; 146 (38) 1800-1802
• 110 Turner MS, May DB, Arthur RR, Xiong GL. Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. J Intern Med 2007; 261 (3) 205-213
• 111 van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323 (7314) 655-658
• 112 Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding?. Am J Med 2006; 119 (9) 719-727
• 113 Monto RW, Talley RW, Caldwell MJ, Levin WC, Guest MM. Observations on the mechanism of hemorrhagic toxicity in mithramycin (NSC 24559) therapy. Cancer Res 1969; 29 (3) 697-704
• 114 Ahr DJ, Scialla SJ, Kimbali Jr DB. Acquired platelet dysfunction following mithramycin therapy. Cancer 1978; 41 (2) 448-454
• 115 Pogliani EM, Fantasia R, Lambertenghi-Deliliers G, Cofrancesco E. Daunorubicin and platelet function. Thromb Haemost 1981; 45 (1) 38-42
• 116 McKenna R, Ahmad T, Ts'ao CH, Frischer H. Glutathione reductase deficiency and platelet dysfunction induced by 1,3-bis(2-chloroethyl)-1-nitrosourea. J Lab Clin Med 1983; 102 (1) 102-115
• 117 Panella TJ, Peters W, White JG, Hannun YA, Greenberg CS. Platelets acquire a secretion defect after high-dose chemotherapy. Cancer 1990; 65 (8) 1711-1716
• 118 Mazharian A, Ghevaert C, Zhang L, Massberg S, Watson SP. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood 2011; 117 (19) 5198-5206
• 119 Oleksowicz L, Zuckerman D, Mrowiec Z, Puszkin E, Dutcher JP. Effects of interleukin-2 administration on platelet function in cancer patients. Am J Hematol 1994; 45 (3) 224-231
• 120 Oleksowicz L, Puszkin E, Mrowiec Z, Isaacs R, Dutcher JP. Alterations in platelet function in patients receiving interleukin-6 as cytokine therapy. Cancer Invest 1996; 14 (4) 307-316
• 121 Grace AA, Barradas MA, Mikhailidis DP , et al. Cyclosporine A enhances platelet aggregation. Kidney Int 1987; 32 (6) 889-895
• 122 Klein BC, Bach D, Rehfeld I , et al. Influence of mycophenolic acid and FK-506 on human platelet activation in vitro. Kidney Blood Press Res 2000; 23 (2) 119-124
• 123 Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979; 2 (8140) 433-435
• 124 Moncada S, Higgs EA. Arachidonate metabolism in blood cells and the vessel wall. Clin Haematol 1986; 15 (2) 273-292
• 125 von Schacky C, Weber PC. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985; 76 (6) 2446-2450
• 126 Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988; 318 (9) 549-557
• 127 Reiter N, Jönsson B, Jansen E, Espersen K. [Vitamin E and excessive bleeding]. Ugeskr Laeger 2005; 167 (49) 4664-4665
• 128 Stuart MJ, Oski FA. Vitamin E and platelet function. Am J Pediatr Hematol Oncol 1979; 1 (1) 77-82
• 129 Norred CL, Finlayson CA. Hemorrhage after the preoperative use of complementary and alternative medicines. AANA J 2000; 68 (3) 217-220
• 130 Cowan DH. Effect of alcoholism on hemostasis. Semin Hematol 1980; 17 (2) 137-147
• 131 Scharf RE, Aul C. [Alcohol-induced disorders of the hematopoietic system]. Z Gastroenterol 1988; 26 (Suppl. 03) 75-83
• 132 James MJ, Walsh JA. Effects of aspirin and alcohol on platelet thromboxane synthesis and vascular prostacyclin synthesis. Thromb Res 1985; 39 (5) 587-593
• 133 Hammerschmidt DE. Szechwan purpura. N Engl J Med 1980; 302 (21) 1191-1193
• 134 Dorso CR, Levin RI, Eldor A, Jaffe EA, Weksler BB. Chinese food and platelets. N Engl J Med 1980; 303 (13) 756-757
• 135 Makheja AN, Bailey JM. Antiplatelet constituents of garlic and onion. Agents Actions 1990; 29 (3-4) 360-363
• 136 Srivastava KC, Mustafa T. Spices: antiplatelet activity and prostanoid metabolism. Prostaglandins Leukot Essent Fatty Acids 1989; 38 (4) 255-266
• 137 Mackenzie IS, Coughtrie MW, MacDonald TM, Wei L. Antiplatelet drug interactions. J Intern Med 2010; 268 (6) 516-529
• 138 Kimmel SE, Berlin JA, Reilly M , et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004; 43 (6) 985-990
• 139 Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci 2010; 55 (7) 1964-1968
• 140 Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010; 31 (8) 810-823
• 141 Bhatt DL, Cryer BL, Contant CF , et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363 (20) 1909-1917
• 142 Müller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003; 108 (18) 2195-2197
• 143 Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004; 109 (11) 1335-1338
• 144 Serebruany VL, Midei MG, Malinin AI , et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004; 164 (18) 2051-2057
• 145 Malmström RE, Ostergren J, Jørgensen L, Hjemdahl P. CASTOR investigators. Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. J Intern Med 2009; 266 (5) 457-466
• 146 Ye Y, Perez-Polo JR, Birnbaum Y. Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions. Ann N Y Acad Sci 2010; 1207: 76-82
• 147 Zotz RB, Scharf RE. [Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia]. Hamostaseologie 2007; 27 (4) 251-262
• 148 Mangano DT, Miao Y, Vuylsteke A , et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297 (5) 471-479